| +0.115 / +1.57%|
PProgenics Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Its pipeline candidates include PSMA ADC, a fully human monoclonal antibody-drug conjugate (ADC) directed toward PSMA and designed to deliver targeted chemotherapy to cancer cells, and MIP-1404, an imaging agent candidate with potential to alter clinical practice in treating prostate cancer. Its principal programs are directed toward gastroenterology, oncology and virology. Progenics Pharmaceuticals was founded by Paul J. Maddon on December 1, 1986 and is headquartered in Tarrytown, NY.
|Mark Robert Baker||President, Chief Executive Officer & Director|
|Angelo William Lovallo||Chief Financial Officer, Treasurer, CAO & VP|
|Robert J. Israel||Executive Vice President-Medical Affairs|
|John W. Babich||Senior Vice President|
|Nitya G. Ray||Senior Vice President-Manufacturing|